APC/C-CDH1 suppresses AROS-mediated protection against DNA damage-induced senescence by ubiquitination.

Ji-Hye Yang, Hanbyeul Choi, Seung Baek Lee, Soo-Jong Um, Eun-Joo Kim

Abstract read

In one paragraph

Article in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ji-Hye YangDepartment of Molecular Biology, Dankook University, Cheonan 31116, Korea.

Hanbyeul ChoiDepartment of Molecular Biology, Dankook University, Cheonan 31116, Korea.

Seung Baek LeeDivision of Radiology, Mayo Clinic, Rochester, MN 55905; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.

Soo-Jong UmDepartment of Integrative Bioscience and Biotechnology/Institute of Bioscience, Sejong University, Seoul 05006, Korea.

Eun-Joo KimDepartment of Molecular Biology, Dankook University, Cheonan 31116, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaphase-promoting complex/cyclosome (APC/C) regulates the cell cycle by destruction of target proteins ubiquitination. However, understanding the control of APC/C has remained elusive. We identify APC2, the catalytic core subunit of APC/C, as a binding partner of active regulator of SIRT1 (AROS). Subsequent immunoprecipitation assays confirm the interaction in vivo. We reveal that AROS competes with APC11 for APC2 binding, thereby impeding the destruction of Cyclin B1. By contrast, the APC/C coactivator CDH1 ubiquitinates and degrades AROS in a D-box-dependent manner. Finally, we demonstrate that CDH1 suppresses the AROS-mediated protection of DNA damage-induced senescence. Overall, our findings provide evidence of the reciprocal role of AROS and APC/C-CDH1 in regulating APC/C activity and DNA damage-induced senescence, and highlight a potential role for AROS in the control of senescence. [BMB Reports 2026; 59(9): 425-431].

Indexed as

Anaphase-Promoting Complex-CyclosomeCdh1 ProteinsCellular SenescenceDNA DamageSirtuin 1Antigens, CDCadherinsCyclin B1HumansProtein BindingUbiquitinationAnaphase-Promoting Complex-CyclosomeAntigens, CDCadherinsCDH1 protein, humanCdh1 ProteinsCyclin B1SIRT1 protein, humanSirtuin 1

Identifiers

PMID40916646

PMCPMC13621194

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.